Evidence map›Paper›PMID 39483520›Full record

ArticleEuropean urology open science2024

Risk Calculator Strategy Before Magnetic Resonance Imaging Stratification for Biopsy-naïve Men with Suspicion for Prostate Cancer: A Cost-effectiveness Analysis.

Konstantius R V Straat, Marinus J Hagens, Leonor J Cools Paulino Pereira, Roderick C N van den Bergh, Jan Willem Mazel, M Arjen Noordzij, Sybren P Rynja

Registry-linked trialAbstract read
In one paragraph

Article in European urology open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07422597 (PRORAND - Prostate Risk or Radiology Assessment Non-inferiority Design, a Comparison of Upfront MRI vs Risk Calculator in Men With Suspected Prostate Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07422597 narecruitingnot on this mapstarted 2026, after this paper: background citation

PRORAND - Prostate Risk or Radiology Assessment Non-inferiority Design, a Comparison of Upfront MRI vs Risk Calculator in Men With Suspected Prostate Cancer

TypeinterventionalSponsorNorwegian University of Science and TechnologyRan2026 to 2029Enrolled1,016ConditionsProstate CancerArmsEuropean Study of screening for prostate cancer risk calculator
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Konstantius R V StraatDepartment of Urology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
Marinus J HagensDepartment of Urology, VUmc site, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Leonor J Cools Paulino PereiraDepartment of Urology, Sint Antonius Hospital, Urology, Nieuwegein, The Netherlands.
Roderick C N van den BerghDepartment of Urology, Sint Antonius Hospital, Urology, Nieuwegein, The Netherlands.
Jan Willem MazelDepartment of Urology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
M Arjen NoordzijDepartment of Urology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
Sybren P RynjaDepartment of Urology, Spaarne Gasthuis, Hoofddorp, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: Current guidelines on prostate cancer (PCa) diagnosis recommend risk stratification before prostate biopsy, using either a risk calculator (RC) or magnetic resonance imaging (MRI). The aim of our study was to assess the effectiveness and cost effectiveness of an RC strategy and a direct MRI (dMRI) strategy. Methods: Data for biopsy-naïve men suspected of having PCa on the basis of elevated prostate specific antigen (PSA) and/or abnormal digital rectal examination (DRE) were retrospectively collected from two large teaching hospitals. The RC and dMRI strategies were evaluated for PCa detection, effectiveness, and costs. The RC strategy used the Rotterdam prostate cancer risk calculator 3/4 and MRI for stratification, while the dMRI strategy directly used MRI findings. Clinically significant (cs)PCa was defined as a Gleason score ≥3 + 4. Key findings and limitations: In total, 1458 men were included for analysis, of whom 944 were in the RC group and 514 were in the dMRI group. The RC strategy significantly reduced MRI use by 47.8% (52.2% vs 99.8%; Conclusions and clinical implications: Both the RC strategy and the dMRI strategy are viable options for PCa diagnosis, with the former significantly reducing MRI use and overall diagnostic costs per person. Therefore, the RC strategy might be preferred over dMRI, particularly in contexts aiming for sustainable health care practices that optimize resource allocation and cost effectiveness. Patient summary: We compared two different approaches for men with a suspicion of prostate cancer. One uses a risk calculator to decide on whether to perform an MRI (magnetic resonance imaging) scan, and the other proceeds directly to MRI. In both cases, prostate biopsy is performed in cases with positive MRI findings. The number of patients who needed a biopsy and the cancer detection rate were similar for the two approaches.

Indexed as

Magnetic resonance imagingProstate cancerRisk calculatorsRisk stratification

Identifiers

PMID39483520
PMCPMC11525455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.